At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pazopanib to Enable Partial Nephrectomy
In Brief
A Phase 2 clinical trial evaluating pazopanib hydrochloride and therapeutic conventional surgery for Clear Cell Renal Cell Carcinoma and 3 related conditions. Completed, enrolled 25 participants across 2 sites.
Detailed Summary
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works when given before surgery in treating patients with kidney cancer.
Study Details
Timeline
Interventions
Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.